Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus

2002879 citationsJournal Articlebronze Open Access

Authors

Steven M. Haffner · Tufts Medical Center

Andrew S. Greenberg · Tufts Medical Center

Wayde M. Weston · Tufts Medical Center

Hongzi Chen · Tufts Medical Center

Ken Williams · Tufts Medical Center

Martin I. Freed · Tufts Medical Center

Abstract

Rosiglitazone reduces serum levels of MMP-9 and the proinflammatory marker CRP in patients with type 2 diabetes, which indicates potentially beneficial effects on overall cardiovascular risk.

Topics & Keywords

Adipokines, Inflammation, and Metabolic Diseases Peroxisome Proliferator-Activated Receptors Protease and Inhibitor Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Circulation

Volume 106, Issue 6, pp. 679-684

DOI: 10.1161/01.cir.0000025403.20953.23

Field-Weighted Citation Impact: 69.95